Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria: Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype Indolent Follicular small cleaved cell Follicular mixed cell Small lymphocytic Mucosa-associated lymphoid tissue (MALT) Monocytoid B-cell Waldenstrom's macroglobulinemia Aggressive Follicular large cell Diffuse large cell Immunoblastic Mantle cell Ki-1+ NHL Peripheral T-cell Angiocentric and angioimmunoblastic Transformed lymphoma Bidimensionally measurable disease No more than 3 prior treatment regimens as follows: Primary radiotherapy is 1 regimen Combined therapy with radiotherapy and chemotherapy is 1 regimen Alternating therapy is 1 regimen No known brain metastases Performance status - ECOG 0-2 Performance status - Karnofsky 50-100% WBC count at least 3,000/mm^3 Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Bilirubin normal SGOT/SGPT no greater than 2.5 times upper limit of normal Creatinine normal Creatinine clearance at least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No neuropathy greater than grade 1 No history of allergy to platinum compounds or antiemetics No uncontrolled illness No active infection Not pregnant or nursing Fertile patients must use effective contraception No concurrent colony-stimulating factors during first course of therapy At least 4 weeks since prior chemotherapy At least 4 weeks since prior radiotherapy No other concurrent investigational drugs No concurrent antiretroviral therapy for HIV-positive patients